Stock Ratings / Health Care / DRUG / financials

EVO (57) PBYI (67) STTK (31) NGNE (36) ⌘ Pro Terminal →

Bright Minds Biosciences Inc. (DRUG) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$56.69 +2.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $56.84

Bright Minds Biosciences Inc. (DRUG) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $556.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $56.84 (+0.26%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DRUG)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY DRUG SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 50.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$54.05-5.1% Next Q

Q2 (-2Q)

Grade C$51.30+2.3% Next Q

Q3 (-1Q)

Grade C$52.48+8% Next Q

Current

Grade C-$56.69+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the DRUG Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, DRUG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($59.18) or 200D SMA ($73.27) invalidates the momentum regime and cuts Target Base ($57.46) toward Bear Floor ($44.82).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DRUG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DRUG Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How DRUG Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$15.6M (0.4% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DRUG)

✓Walkthrough of DRUG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DRUG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.54%▼ DESCENDING CHANNEL

2026-10-30O $56.90H $57.00L $54.96C $56.69VOL 95.8K

RES: $82.60SUP: $45.22SMA50: $59.18SMA200: $73.27

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DRUG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DRUG Butterfly Map → + Track DRUG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DRUG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DRUG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DRUG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DRUG)

Health Care Rank #189 of 1016 ⚔️ EVO vs DRUG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DRUG vs. EVO, PBYI, STTK, NGNE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bright Minds Biosciences Inc. (DRUG) ranks #189 by composite RQD confidence (61/100, grade C-) and #430 by equity capitalization ($556.7M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with DRUG at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DRUG ACTIVE Bright Minds Biosciences Inc.	C-	61/100	—	—	—	+2.48%	$556.7M	Benchmark Subject
EVO Evotec SE	D+	57/100	—	—	—	-1.56%	$562.1M	/evo-vs-drug →
PBYI Puma Biotechnology Inc	C+	67/100	17.5x	74.5%	29.3%	-0.75%	$544.1M	/pbyi-vs-drug →
STTK Shattuck Labs Inc.	E	31/100	—	—	-35.0%	-1.46%	$574.1M	/sttk-vs-drug →
NGNE Neurogene Inc.	D-	36/100	—	—	-35.0%	-5.26%	$576.7M	/ngne-vs-drug →

2. DRUG Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Bright Minds Biosciences Inc. (DRUG) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $556.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. DRUG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DRUG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bright Minds Biosciences Inc. (NASDAQ: DRUG) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $56.69 (+2.48% 1D, market cap $556.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, DRUG ranks #189 in composite RQD confidence.

How does DRUG compare to EVO and PBYI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DRUG carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EVO (Evotec SE) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $562.1M) and PBYI (Puma Biotechnology Inc) posts a C+ grade (67/100 RQD, P/E 17.5x, ROIC 29.3%, cap $544.1M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DRUG?

For Bright Minds Biosciences Inc. (DRUG), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #189 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DRUG trading relative to its 50-day, 200-day, and 52-week technical levels?

DRUG last traded at $56.69 (+2.48% on volume of 67,555 shares), positioning the stock -4.21% below its 50-day simple moving average ($59.18) and -22.63% below its 200-day simple moving average ($73.27). Across its 52-week range of $47.23 to $123.75, DRUG sits at the 12.4% percentile with a 14-day RSI of 50.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($49.60 to $63.78).